T. Rowe Price Investment Management, Inc. filed a Schedule 13G with the SEC on November 16, 2026, disclosing a beneficial ownership position in Oruka Therapeutics Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 4,392,166 shares of Oruka Therapeutics Inc. common stock.
- Percent of class: The reported position represents 6.6% of the class of common stock, according to the filing.
- Sole voting power: The filing states sole voting power over 4,216,126 shares.
- Sole dispositive power: Sole power to dispose of or direct the disposition of 4,392,166 shares is reported, with no shared dispositive power.
- Triggering event date: The date of the event requiring the filing is listed as September 30, 2026.
- Filer type: T. Rowe Price Investment Management, Inc. is identified as an investment adviser (type "IA") incorporated in Maryland.
T. Rowe Price Investment Management Reports Position in Oruka Therapeutics Common Stock
According to the Schedule 13G filed on November 16, 2026, T. Rowe Price Investment Management, Inc., headquartered at 1307 Point Street, Baltimore, MD 21231, disclosed a beneficial ownership stake in Oruka Therapeutics Inc. (NASDAQ:ORKA), whose principal executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025. The filing was triggered by an event dated September 30, 2026, and covers common stock with CUSIP number 687604108.
The filing reports aggregate beneficial ownership of 4,392,166 shares, equating to 6.6% of the outstanding class of common stock. Of those shares, the filing states that T. Rowe Price Investment Management holds sole voting power over 4,216,126 shares and sole dispositive power over all 4,392,166 shares. Shared voting power and shared dispositive power are each reported as zero.
The filing was signed by Ellen York, Vice President of T. Rowe Price Investment Management, Inc., on November 16, 2026. Per the certification included in the filing, the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing also includes a declaration that it "shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
What Was Disclosed
T. Rowe Price Investment Management, Inc. disclosed a 6.6% beneficial ownership position, totaling 4,392,166 shares, in Oruka Therapeutics Inc. common stock via a Schedule 13G, with a triggering event date of September 30, 2026.




Please wait processing your request...